AmyElizabethDezernMD

PubMed

• Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclop...
  Jonaphine Rae Mata, Marianna Zahurak, Natalie Rosen, Amy E DeZern, Richard J Jones, Alexander J Ambinder> ;Transplantation and Cellular Therapy. 2024 Mar 22
• SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
  Michael J Hochman, Amy E DeZern> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 18
• 3 citations
  Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...
  Garcia-Manero, G., McCloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H., Patel, P., Sabloff, M., Keating, M., Zhu, N., Gabrail, N., Fazal, S., Maly...> ;The Lancet. Haematology. 2024 Jan 1
• 1 citations
  The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
  Peter L Greenberg, Amy E DeZern> ;Blood. 2023 Dec 28
• Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
  DeZern, A., Stahl, M.> ;The Lancet. Haematology. 2024 Jan 1
• 4 citations
  Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
  Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
• 1 citations
  Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia.
  Amy E DeZern, Marianna Zahurak, Richard J Jones, Robert A Brodsky> ;Haematologica. 2024 Feb 1
• 1 citations
  Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
  Edward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M Foran, Jane Jijun Liu, Rafael Bejar, Steven D Gore, Steven H Kroft, Alexandra Harrington...> ;Blood Advances. 2023 Oct 24
• Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
  Michael J Hochman, Megan Othus, Robert P Hasserjian, Alex Ambinder, Andrew Brunner, Mary-Elizabeth M Percival, Christopher S Hourigan, Ronan Swords, Amy E DeZern, Elih...> ;Leukemia. 2023 Sep 1
• 1 citations
  An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes.
  Patric Teodorescu, Sergiu Pasca, InYoung Choi, Cynthia Shams, W Brian Dalton, Lukasz P Gondek, Amy E DeZern, Gabriel Ghiaur> ;Haematologica. 2024 Jan 1
• 1 citations
  Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes.
  Sergiu Pasca, Matthew Z Guo, Shiyu Wang, Kristin Stokvis, Audra Shedeck, Aparna Pallavajjala, Cynthia Shams, Roshni Pallavajjala, Amy E DeZern, Ravi Varadhan, Christop...> ;Blood Advances. 2023 Aug 22
• 1 citations
  The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelod...
  Sandeep Gurbuxani, Michael J Hochman, Amy E DeZern, Akiko Shimamura> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 Jun 1
• 3 citations
  Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
  Gregory A Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wa...> ;Blood Advances. 2023 Jul 25
• 9 citations
  Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia.
  Amy E DeZern, Marianna Zahurak, Heather J Symons, Kenneth R Cooke, Carol Ann Huff, Tania Jain, Lode J Swinnen, Philip H Imus, Nina D Wagner-Johnston, Richard F Ambinde...> ;Blood. 2023 Jun 22
• 1 citations
  Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study.
  Tao Zhang, Paul Auer, Jing Dong, Corey Cutler, Amy E Dezern, Shahinaz M Gadalla, H Joachim Deeg, Aziz Nazha, Karen-Sue Carlson, Stephen Spellman, Yung-Tsi Bolon, Wael ...> ;Journal of Hematology & Oncology. 2023 Apr 11
• 4 citations
  Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
  Amy E DeZern, Johannes B Goll, R Coleman Lindsley, Rafael Bejar, Steffanie H Wilson, Donnie Hebert, Joachim Deeg, Ling Zhang, Steven Gore, Tareq Al Baghdadi, Jaroslaw ...> ;Blood Advances. 2023 Jul 25
• 6 citations
  Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement.
  Matteo Di Nardo, Graeme MacLaren, Peter Schellongowski, Elie Azoulay, Amy E DeZern, Cristina Gutierrez, Massimo Antonelli, Marta V Antonini, Gernot Beutel, Alain Combe...> ;The Lancet. Respiratory Medicine. 2023 May 1
• 6 citations
  Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1International Workshop on MDS (iwMDS) Of t...
  Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, Uma Borate, Jacqueline Boultwood, Andrew M Brunner, Rena Buckstein, Hetty E Carraway, Jane E Churpek, Naval G Daver, ...> ;Blood Reviews. 2023 Jul 1
• Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation.
  Jing Dong, Christopher Staffi Buradagunta, Tao Zhang, Stephen Spellman, Yung-Tsi Bolon, Amy E DeZern, Shahinaz M Gadalla, H Joachim Deeg, Aziz Nazha, Corey Cutler, Cha...> ;Journal of Hematology & Oncology. 2023 Mar 10
• 3 citations
  Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
  Khaled Sanber, Kevin Ye, Hua-Ling Tsai, Matthew Newman, Jonathan A Webster, Ivana Gojo, Gabriel Ghiaur, Gabrielle T Prince, Lukasz P Gondek, B Douglas Smith, Mark J Le...> ;Leukemia & Lymphoma. 2023 Apr 1
• 1 citations
  On the basis of sex: outcomes in myelodysplastic syndromes.
  Michael J Hochman, Amy E DeZern> ;The Lancet. Haematology. 2023 Feb 1
• 28 citations
  Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
  Amer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Adès, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E Carraway, Naval...> ;Blood. 2023 Apr 27
• 3 citations
  Considerations for Drug Development in Myelodysplastic Syndromes.
  Mikkael A Sekeres, Nina Kim, Amy E DeZern, Kelly J Norsworthy, Jacqueline S Garcia, R Angelo de Claro, Marc R Theoret, Emily Y Jen, Lori A Ehrlich, Amer M Zeidan, Rami...> ;Clinical Cancer Research. 2023 Jul 14
• Are We Ready For "Triplet" Therapy in Higher-Risk MDS?
  Andrew M Brunner, Uwe Platzbecker, Amy E DeZern, Amer M Zeidan> ;Clinical Hematology International. 2023 Jan 1
• 1 citations
  Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
  Cole H Sterling, Michael S Hughes, Hua-Ling Tsai, Kathryn Yarkony, Ephraim J Fuchs, Lode J Swinnen, Suman Paul, Javier Bolaños-Meade, Leo Luznik, Philip H Imus, Syed A...> ;Transplantation and Cellular Therapy. 2023 Apr 1
• Join now to see all

Abstracts/Posters

• Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
  Amy E. DeZern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tole... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• ASH Networking Reception for Women in Hematology 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• 17th Update in Hematologic Malignancies 
  The Johns Hopkins University School of Medicine, Baltimore, Maryland - 4/26/2013
• Join now to see all